Illumina, Inc. $ILMN Stock Acquired by Ethic Inc.

Ethic Inc. increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 23.4% in the third quarter, Holdings Channel.com reports. The firm owned 22,294 shares of the life sciences company’s stock after purchasing an additional 4,224 shares during the quarter. Ethic Inc.’s holdings in Illumina were worth $6,101,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Illumina in the 2nd quarter valued at approximately $3,374,423,000. WCM Investment Management LLC boosted its position in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after acquiring an additional 1,851,848 shares during the last quarter. Primecap Management Co. CA acquired a new position in Illumina during the 2nd quarter worth approximately $617,981,000. Ninety One UK Ltd grew its stake in shares of Illumina by 37,920.0% during the 3rd quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company’s stock worth $372,198,000 after acquiring an additional 1,356,397 shares in the last quarter. Finally, Jupiter Topco LLC bought a new position in shares of Illumina during the 2nd quarter worth approximately $358,652,000. Institutional investors own 89.42% of the company’s stock.

Insider Activity

In related news, Director Keith Meister sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $227.17, for a total transaction of $11,358,500.00. Following the sale, the director owned 488,917 shares in the company, valued at approximately $111,067,274.89. This trade represents a 9.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders have sold 1,601,541 shares of company stock worth $354,755,291. Company insiders own 2.90% of the company’s stock.

Illumina Stock Performance

Shares of ILMN opened at $220.78 on Tuesday. The firm has a 50-day moving average of $249.25 and a 200-day moving average of $178.46. The company has a market cap of $33.38 billion, a PE ratio of 43.15, a price-to-earnings-growth ratio of 3.08 and a beta of 1.46. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.63 and a quick ratio of 2.05. Illumina, Inc. has a one year low of $112.65 and a one year high of $309.35.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.26. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The company’s revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.34 earnings per share. As a group, equities analysts forecast that Illumina, Inc. will post 5.43 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of Illumina to a “hold” rating in a report on Wednesday, August 5th. Guggenheim increased their target price on shares of Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. UBS Group raised shares of Illumina from a “neutral” rating to a “buy” rating and raised their target price for the company from $135.00 to $260.00 in a research report on Wednesday, September 9th. Canaccord Genuity Group lifted their price target on shares of Illumina from $205.00 to $300.00 and gave the company a “hold” rating in a research note on Monday, October 19th. Finally, Evercore reiterated an “underperform” rating on shares of Illumina in a research note on Friday, October 30th. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $244.24.

Illumina Profile

Illumina, Inc develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data.

The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers internationally.